Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHEN26 in mild to moderate COVID-19
NCT05676073Phase 2Completed
- Sponsor
- Kexing Biopharm
- Start
- Dec 2022
- Primary completion
- Dec 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obeldesivir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Kexing Biopharm. Primary endpoint: SARS-CoV-2 viral RNA level (RT-PCR) at Day 7. Started Dec 2022; status: completed.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05676073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676073.